Arcus Biosciences, Inc. (RCUS) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2022
Loading P/E history...
RCUS Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 6, 2026, Arcus Biosciences, Inc. (RCUS) trades at a price-to-earnings ratio of -7.9x, with a stock price of $26.06 and trailing twelve-month earnings per share of $-2.94.
The current P/E is 115% below its 5-year average of 52.9x. Over the past five years, RCUS's P/E has ranged from a low of 25.9x to a high of 94.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.2x, RCUS trades at a 136% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 171.0x.
Relative to the broader market, RCUS trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RCUS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
RCUS P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $11B | 16.0 | 0.31Best | +58% | |
| $8B | 25.7 | 1.12 | -25% | |
| $6B | 240.7 | - | +76% | |
| $19B | 15.2Lowest | - | +4173%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
RCUS Historical P/E Data (2021–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $26.16 | $1.01 | 25.9x | -51% |
| FY2022 Q2 | $25.34 | $0.74 | 34.2x | -35% | |
| FY2022 Q1 | $31.56 | $0.55 | 57.4x | +8% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $40.47 | $0.43 | 94.1x | +78% |
Average P/E for displayed period: 52.9x
See RCUS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RCUS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RCUS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRCUS — Frequently Asked Questions
Quick answers to the most common questions about buying RCUS stock.
Is RCUS stock overvalued or undervalued?
RCUS trades at -7.9x P/E, below its 5-year average of 52.9x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does RCUS's valuation compare to peers?
Arcus Biosciences, Inc. P/E of -7.9x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is RCUS's PEG ratio?
RCUS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2022.